Clinical Trial Update: Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

View source ↗

Summary

A clinical trial is evaluating adjuvant therapy with neratinib for patients with HER2-positive breast cancer and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nerlynx (neratinib)

Snippet

Sponsor: Shu Wang | Conditions: HER2-positive Breast Cancer | Status: RECRUITING